GAVI Board Teleconference
8 March 2001
Topics:
Outcome of Third Review
of Country Proposals
The Board generally endorsed the recommendations
of the independent review committee and requests that the Vaccine
Fund provide financial support to Armenia for the introduction of
new and under-used vaccines, and to Burkina Faso and Sierra Leone
for immunization services strengthening, in accordance with their
respective proposals.
The Board further decided in principle to request
that the Vaccine Fund provide financial support to Cameroon, Pakistan
and Tajikistan for immunization services strengthening, pending
the clarifications requested from these countries.
The falling proportion of proposals being approved
in successive rounds is highlighting the need for increased support
to countries so that they can submit successful proposals to GAVI
/ the Vaccine Fund. The partners, particularly WHO and UNICEF with
the Task Force on Country Coordination, will as a matter of urgency,
increase their efforts to provide the technical support necessary
to help countries conduct immunization assessments, develop multiyear
immunization and new vaccine introduction plans, and strengthen
coordination among partners through a strong ICC.
Concern was raised about the Nepal request for hepatitis
B vaccine which was not recommended for approval. The Board urged
that GAVI partners, in coordination with the Task Force on Country
Coordination, provide the necessary support to Nepal to address
the areas required to improve its system and submit a successful
proposal to GAVI / the Vaccine Fund as soon as possible.
On an interim basis, a minimum investment support
of US$ 30,000 over two years from the sub-account for immunization
services was endorsed. The Secretariat together with the Working
Group were requested to examine the issue more closely to ascertain
whether this amount is appropriate. A proposed policy will be presented
to the the Board in June; retroactive payments will be made thereafter
to countries concerned.
The Secretariat will in the future provide the Board
with an analysis of the impact of the proposal review recommendations
that reflects the estimated number of children to be reached, to
supplement the information concerning financial commitments.
GAVI Workplan 2001
The Board commended the workplan as an important
GAVI instrument.
The Board asked the Secretariat and the Working Group
to propose a comprehensive policy for discussion at the June meeting
regarding capacity of vaccine manufacturers in developing countries,
including technology transfer.
The Board proposed that the workplan better reflect
the need to improve capacity of countries to provide the basic immunization
services.
The workplan will be updated based on the written
comments submitted by Dr Borst-Eilers and the discussion during
the teleconference, and re-circulated to the Board.
Update from the Working
Group
Capacity building: The Board endorsed the suggested
that the strategy should include more details of how country programs
will be supported, beyond ICCs.
Global Fund and GAVI: The Board expressed concern
about the risk that GAVI and the Vaccine Fund could diverge courses,
especially considering the current exercise to develop an identifiable
brand for the Vaccine Fund for use in fundraising efforts
in the United States. The Board confirmed that the two must be viewed
as closely linked.The Secretariat was requested to work with the
Working Group and the Vaccine Fund Secretariat to prepare for the
Board an analysis of pros and cons of more closely integrating GAVI
and the Vaccine Fund in order to reduce confusion about the respective
roles of the two Boards and Secretariats. Until a more informed
discussion in June, communication about GAVI and the Vaccine Fund
will continue to convey their close relationship.
The Board valued the update from the Working Group
and requested that in the future similar updates be distributed
to the Board prior to teleconferences and as other needs arise.
Next meeting of the GAVI Board
The Board appreciates the offer from DfID to
host the next GAVI Board meeting in London, and agreed to the dates
of 21-22 June.
Mr Lovelace requested that the issue of how GAVI
will fit in relation to other new global health initiatives be on
the agenda of the June Meeting. The Board accepted his offer to
prepare a background paper for the Board.
Return to GAVI Board
Documents
|